Viridian Therapeutics, Inc.\DE (VRDN) Cash from Operations (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Cash from Operations history runs 14 years deep, the most recent figure standing at 119654000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 29.14% year-over-year to 119654000.0; the TTM figure through Mar 2026 stood at 303392000.0 (down 8.45% YoY), while the FY2025 annual figure was 276391000.0, down 18.97% from the prior year.
• Cash from Operations for Q1 2026 stood at 119654000.0, down from 23754000.0 in the prior quarter.
• The five-year high for Cash from Operations was 18086000.0 in Q2 2022, with the low at 119654000.0 in Q1 2026.
• The 5-year median for Cash from Operations is 45223000.0 (2024), against an average of 53316000.0.
• The sharpest annual moves came in 2023 and 2025: Cash from Operations sank 194.52% in 2023, then surged 67.61% in 2025.
• Viridian Therapeutics, Inc.\DE's Cash from Operations stood at 34042000.0 in 2022, then slipped by 11.63% to 38000000.0 in 2023, then sank by 92.98% to 73332000.0 in 2024, then soared by 67.61% to 23754000.0 in 2025, then slumped by 403.72% to 119654000.0 in 2026.
• Business Quant data shows VRDN's Cash from Operations at 119654000.0 in Q1 2026, 23754000.0 in Q4 2025, and 84611000.0 in Q3 2025.